# CAPItello-292 (NCT04862663)

> Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04862663
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions: Capivasertib; Fulvestrant; Palbociclib; Ribociclib; Abemaciclib
- Enrollment: 893
- Primary outcome: Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.
- Primary outcome: Phase Ib: 2. The number of participants with treatment-related adverse events.
- Primary outcome: Phase Ib: 3. The number of participants with treatment-related serious adverse events.
- Primary outcome: Phase III: 1. Progression Free Survival (PFS).

## Commentary we found

- YouTube: 15
- Podcasts: 13
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=capitello-292-nct04862663

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04862663", "email": "<work email>"}; the inbox owner confirms by the emailed link.